Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation

作者：W. Brian Dalton, Eric Helmenstine, Noel Walsh, Lukasz P. Gondek, Dhanashree Kelkar, Abigail Read, Rachael Natrajan, Eric S. Christenson, Bárbara Román, Samarjit Das, Liang Zhao, Robert D. Leone, Daniel Shinn, Taylor Groginski, Anil K. Madugundu, Arun H. Patil, Daniel J. Zabransky, Arielle J. Medford, Justin Lee, Alex J. Cole, Marc Rosen, Maya Thakar, Alexander J. Ambinder, Joshua Donaldson, Amy E. DeZern, Karen Cravero, David Chu, Rafael Madero‐Marroquin, Akhilesh Pandey, Paula J. Hurley, Josh Lauring, Ben Ho Park · 发表于：Journal of Clinical Investigation · 年份：2019 · DOI：10.1172/jci125022 · 被引用次数：68 · 研究领域：RNA Research and Splicing、RNA modifications and cancer、Epigenetics and DNA Methylation

Cancer-associated mutations in the spliceosome gene SF3B1 create a neomorphic protein that produces aberrant mRNA splicing in hundreds of genes, but the ensuing biologic and therapeutic consequences of this missplicing are not well understood. Here we have provided evidence that aberrant splicing by mutant SF3B1 altered the transcriptome, proteome, and metabolome of human cells, leading to missplicing-associated downregulation of metabolic genes, decreased mitochondrial respiration, and suppression of the serine synthesis pathway. We also found that mutant SF3B1 induces vulnerability to deprivation of the nonessential amino acid serine, which was mediated by missplicing-associated downregulation of the serine synthesis pathway enzyme PHGDH. This vulnerability was manifest both in vitro and in vivo, as dietary restriction of serine and glycine in mice was able to inhibit the growth of SF3B1MUT xenografts. These findings describe a role for SF3B1 mutations in altered energy metabolism, and they offer a new therapeutic strategy against SF3B1MUT cancers.